Dr. Leis is on Doximity
As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5881 E Mayo Blvd
Phoenix, AZ 85054Phone(480) 342-2501
Fax(480) 301-4675- Is this information wrong?
Summary
- Dr. Jose Leis is an oncologist in Scottsdale, AZ and is affiliated with Mayo Clinic Hospital. He received his medical degree from University of Arizona College of Medicine - Tucson and has been in practice 31 years. He specializes in hematologic oncology and is experienced in acute and chronic leukemias, lymphoma, myelodysplasia, myelofibrosis, and bone marrow transplantation.
Education & Training
Brigham and Women's HospitalFellowship, Hematology, 1989 - 1993
University of California San DiegoResidency, Internal Medicine, 1986 - 1989
University of Arizona College of Medicine - TucsonClass of 1986
Certifications & Licensure
AZ State Medical License 2007 - 2021
OR State Medical License 1997 - Present- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Press Ganey Top Provider Recognition Award Office of Mayo Clinic Experience, Mayo Clinic Arizona, 2020
- Top Doctors:Arizona State Castle Connolly, 2013-2020
- Top Faculty Award Mayo School of Continuous Professional Development, 2011-2012
- Join now to see all
Clinical Trials
- Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Start of enrollment: 2010 Aug 01Lanasa, M.,Leis, J.,Shanafelt, T.,Tun, H.W.
- Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2009 Jul 01Zent, C.S.,Leis, J.F.
- Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2008 Feb 01Tun, H.W.,Leis, J.F.,Shanafelt, T.D.
- Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Start of enrollment: 2005 Aug 01Leis, J.F.,Shanafelt, T.D.
- Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Sameer Parikh
- PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB Leis, J.F.
Publications & Presentations
PubMed
- Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantationLuke Mountjoy, Jeanne Palmer, Katie L. Kunze, Nandita Khera, Lisa Z. Sproat, Jose F. Leis, Pierre Noel, James L. Slack, Tania Jain> ;Leukemia & Lymphoma. 2021 Jan 2
- Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.Paul J. Hampel, Timothy G. Call, Kari G. Rabe, Wei Ding, Eli Muchtar, Saad S. Kenderian, Yucai Wang, Jose F. Leis, Thomas E. Witzig, Amber B. Koehler, Amie Fonder, Sus...> ;Oncologist. 2020 Nov 1
- Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.Koehler, A. B., Leung, N., Call, T. G., Rabe, K. G., Achenbach, S. J., Ding, W., Kenderian, S. S., Leis, J. F., Wang, Y., Muchtar, E., Hayman, S. R., Hampel, P. J., Fi...> ;Leukemia & lymphoma. 2020 May 26
- Join now to see all
Abstracts/Posters
- Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphoc...Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell LymphocytosisJose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Management of Steroid Resistant Acute and Chronic GVHD: Are We Making Progress?CIBMTR and ASBMT BMT Tandem Meeting, Salt Lake City, UT - 2/2018
- CLL: What To Do After BTK Inhibitor Therapy FailsGreat Debates & Updates in Hematologic Malignancies, New York, NY - 4/2018
- How I Treat Newly Diagnosed, Relapsed, and Transformed CLL PatientsAmerican Society of Hematology (ASH) Meeting on Hematologic Malignancies, Chicago, IL - 9/2019
- Join now to see all
Professional Memberships
- Member
- Member
- American Society for Blood and Marrow TransplantationMember
- European Society of HematologyMember
Hospital Affiliations
Mayo Clinic HospitalPhoenix, Arizona
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
